

=> d ibib abs ind hitstr l5 1-1

L5 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:521523 HCAPLUS

DOCUMENT NUMBER: 137:73273

TITLE: Adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain

INVENTOR(S): Gil, Daniel W.; Aoki, Kei Roger

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053177	A2	20020711	WO 2001-US48651	20011214
WO 2002053177	A3	20030918		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6787517	B1	20040907	US 2000-751053	20001229
CA 2433332	AA	20020711	CA 2001-2433332	20011214
EP 1363674	A2	20031126	EP 2001-990212	20011214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004146532	A1	20040729	US 2004-791434	20040301
PRIORITY APPLN. INFO.:			US 2000-751053	A 20001229
			WO 2001-US48651	W 20011214

OTHER SOURCE(S): MARPAT 137:73273

AB Agents for treating pain, methods for producing the agents, and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent, are disclosed. The agent may include a clostridial neurotoxin, a fragment or a derivative thereof, attached to a targeting component, wherein the targeting component is selected from a group consisting of compds. which selectively binds at the $\alpha 2b$ or $\alpha 2b/\alpha 2c$ adrenergic receptor subtype(s) as compared to other binding sites, e.g. the $\alpha 2a$ adrenergic receptor subtype.

IC ICM A61K039-00

CC 1-11 (Pharmacology)

Section cross-reference(s): 63

ST adrenergic receptor ligand neurotoxin conjugate analgesic

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(MBP (maltose-binding protein), fusion products; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)

IT Analgesics

Cytoplasm

Drug delivery systems

Human

Ribosome

- (adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Amino acids, biological studies
Gene
Neurotransmitters
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Antibodies and Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Pain
Skin, disease
(allodynia; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Toxins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(butyricum, conjugates; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Pain
(chronic; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Hemocyanins
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(conjugates; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Proteins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Viscera
(disease, pain; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Drug delivery systems
(injections, i.m.; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Drug delivery systems
(injections, s.c.; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Biological transport
(intracellular; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Drug delivery systems
(intrathecal; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Nerve, disease
(neuropathy, neuropathic pain; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Pain
(referred; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)
- IT Proteins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(saporins, conjugates; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)

IT Hydrocarbons, biological studies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(spacer; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)

IT Toxins
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetanus, conjugates; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)

IT Disease, animal
(visceral pain; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)

IT Pain
(visceral; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)

IT Antigens
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(α 2b receptor second extracellular loop; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)

IT Adrenoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 2B; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)

IT Adrenoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α 2C; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)

IT 440645-44-3
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)

IT 19216-56-9D, Prazosin, conjugates 61290-32-2D, conjugates 67339-62-2D, ARC 239, conjugates 81167-16-0D, Imiloxan, conjugates 93384-43-1D, Botulin A, conjugates 93384-44-2D, Botulin B, conjugates 93384-46-4D, Botulin D, conjugates 93384-47-5D, Botulin E, conjugates 107231-12-9D, Botulin, conjugates 107231-13-0D, Botulin C1, conjugates 107231-15-2D, Botulin F, conjugates 107231-16-3D, Botulin G, conjugates 366786-91-6D, conjugates
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)

IT 147-85-3, L-Proline, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(proline-containing polypeptide, spacer; adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)


IT 440645-44-3
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)

RN 440645-44-3 HCAPLUS


CN L-Glutamic acid, L-lysylglycyl-L- α -aspartyl-L-glutaminyglycyl-L-prolyl-L-glutaminy-L-prolyl-L-arginylglycyl-L-arginyl-L-prolyl-L-glutaminy-L-cysteinyl-L-lysyl-L-leucyl-L-asparaginy-L-glutaminy- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C



IT 19216-56-9D, Prazosin, conjugates 61290-32-2D, conjugates 67339-62-2D, ARC 239, conjugates 81167-16-0D, Imiloxan, conjugates 93384-43-1D, Botulin A, conjugates 93384-44-2D, Botulin B, conjugates 93384-46-4D, Botulin D, conjugates 93384-47-5D, Botulin E, conjugates 107231-12-9D, Botulin, conjugates 107231-13-0D, Botulin C1, conjugates 107231-15-2D, Botulin F, conjugates 107231-16-3D, Botulin G, conjugates 366786-91-6D, conjugates
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (adrenergic receptor ligand-neurotoxin conjugates and methods for treating pain)


RN 19216-56-9 HCAPLUS

CN Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-(9CI) (CA INDEX NAME)




RN 61290-32-2 HCAPLUS


CN Thiourea, N-[(4-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 67339-62-2 HCAPLUS
CN 1,3(2H,4H)-Isoquinolinedione, 2-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 81167-16-0 HCAPLUS
CN 1H-Imidazole, 2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1-ethyl- (9CI)
(CA INDEX NAME)



RN 93384-43-1 HCAPLUS
CN Botulin A (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 93384-44-2 HCAPLUS
CN Botulin B (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 93384-46-4 HCAPLUS
CN Botulin D (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 93384-47-5 HCAPLUS
CN Botulin E (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 107231-12-9 HCAPLUS
CN Botulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 107231-13-0 HCAPLUS
CN Botulin C1 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 107231-15-2 HCAPLUS
CN Botulin F (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


RN 107231-16-3 HCAPLUS

CN Botulin G (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 366786-91-6 HCAPLUS

CN Thiourea, N-[(3-chloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




IT 147-85-3, L-Proline, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(proline-containing polypeptide, spacer; adrenergic receptor
ligand-neurotoxin conjugates and methods for treating pain)

RN 147-85-3 HCAPLUS

CN L-Proline (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



=> d his ful

FILE 'HCAPLUS' ENTERED AT 17:53:20 ON 28 FEB 2005

L1 E GIL DANIEL/AU
42 SEA ABB=ON ("GIL DANIEL"/AU OR "GIL DANIEL W"/AU OR "GIL
DANIEL WALTER"/AU)
E AOKI KEI/AU
L2 71 SEA ABB=ON ("AOKI KEI"/AU OR "AOKI KEI ROGER"/AU)
L3 1 SEA ABB=ON L1 AND L2
SELECT RN L3 1-1

FILE 'REGISTRY' ENTERED AT 17:54:11 ON 28 FEB 2005

L4 15 SEA ABB=ON (107231-12-9/BI OR 107231-13-0/BI OR 107231-15-2/BI
OR 107231-16-3/BI OR 147-85-3/BI OR 19216-56-9/BI OR 366786-91
-6/BI OR 440645-44-3/BI OR 61290-32-2/BI OR 67339-62-2/BI OR
81167-16-0/BI OR 93384-43-1/BI OR 93384-44-2/BI OR 93384-46-4/B
I OR 93384-47-5/BI)

FILE 'HCAPLUS' ENTERED AT 17:54:19 ON 28 FEB 2005

L5 1 SEA ABB=ON L3 AND L4
D IBIB ABS IND HITSTR L5 1-1
L6 ANALYZE L5 1-1 CT : 22 TERMS

FILE 'REGISTRY' ENTERED AT 17:56:32 ON 28 FEB 2005

L7 STR
L8 0 SEA SSS SAM L7
L9 0 SEA SSS FUL L7
L10 STR L7
L11 0 SEA SSS SAM L10
L12 0 SEA SSS FUL L10
L13 STR L10
L14 0 SEA SSS SAM L13
L15 0 SEA SSS FUL L13
L16 STR L13
L17 9 SEA SSS SAM L16
L18 161 SEA SSS FUL L16


161 compds from Reg. - see d'que stat "

FILE 'HCAPLUS' ENTERED AT 18:09:56 ON 28 FEB 2005

L19 11 SEA ABB=ON L18 AND (?PAIN? OR ?ANALGES? OR ?ADRENERG? OR
?ADRENOCEPT?)

11 citz from C.A. Plus with Test Terms

=> d que stat l19
L16 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 8

STEREO ATTRIBUTES: NONE
L18 161 SEA FILE=REGISTRY SSS FUL L16
L19 11 SEA FILE=HCAPLUS ABB=ON L18 AND (?PAIN? OR ?ANALGES? OR
?ADRENERG? OR ?ADRENOCEPT?)

=> d ibib abs hitstr l19 1-11

L19 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:331968 HCAPLUS

DOCUMENT NUMBER: 140:332518

TITLE: α 2B or α 2B/2C **Adrenoceptor**
agonists for the treatment of neurodegeneration

INVENTOR(S): Wheeler, Larry A.; Gil, Daniel W.; Donello, John E.

PATENT ASSIGNEE(S): Allergan, Inc., USA

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004032913	A1	20040422	WO 2003-US31809	20031007
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004138312	A1	20040715	US 2003-680879	20031007

PRIORITY APPLN. INFO.:

US 2002-417049P P 20021008

AB The invention discloses methods using α 2B or α 2B/2C

adrenoceptor agonists for preventing or retarding the degeneration of neurons. Also disclosed are methods for treating Alzheimer's disease or Parkinson's disease through the administration of selective α 2B or α 2B/2C **adrenoceptor** agonists.


IT 366786-91-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(α 2B or α 2B/2C **adrenoceptor** agonists for treatment of neurodegeneration)

RN 366786-91-6 HCAPLUS

CN Thiourea, N-[(3-chloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L19 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:950846 HCAPLUS


DOCUMENT NUMBER: 140:13072

TITLE: Novel methods and compositions for alleviating **pain**
 INVENTOR(S): Gil, Daniel W.; Donello, John E.
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: PCT Int. Appl., 129 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099289	A2	20031204	WO 2003-US13057	20030423
WO 2003099289	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003229088	A1	20031211	US 2002-153154	20020521
EP 1507536	A2	20050223	EP 2003-724272	20030423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004132824	A1	20040708	US 2003-735506	20031211
PRIORITY APPLN. INFO.:			US 2002-153154	A 20020521
			WO 2003-US13057	W 20030423
AB The invention provides a method for the long-term relief of chronic pain in a subject by activating in the subject an analgesic α - adrenergic receptor in the absence of α -2A receptor activation over a period of at least three days, such that relief of chronic pain is maintained in the absence of continued activation of said receptor. The analgesic α - adrenergic receptor can be, for example, the α -2B receptor.				
IT 366786-91-6 629628-15-5 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (α - adrenoceptor activation for alleviating pain)				
RN 366786-91-6 HCAPLUS CN Thiourea, N-[(3-chloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)				




RN 629628-15-5 HCAPLUS
 CN Thiourea, N-[(2-fluoro-3-methylphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
 (CA INDEX NAME)



L19 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:334962 HCAPLUS
 DOCUMENT NUMBER: 138:331737
 TITLE: Methods and compositions for modulating α adrenergic receptor activity, and therapeutic use thereof
 INVENTOR(S): Chow, Ken; Gil, Daniel W.; Fang, Wenkui Ken; Garst, Michael E.; Wheeler, Larry A.
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035178	A1	20030501	WO 2002-US32571	20021011
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003092766	A1	20030515	US 2001-39827	20011019
PRIORITY APPLN. INFO.:			US 2001-39827	A 20011019
OTHER SOURCE(S):	MARPAT 138:331737			
GI				



I

AB Methods and compns. are discloses for the treatment of **pain** and intraocular pressure. Particularly disclosed are compns. for the treatment of chronic **pain**, glaucoma, and methods for their use.

Compds. of the invention include e.g. I (preparation given).


IT 61290-32-2P 366786-91-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(thiourea derivs., preparation and use in treatment of glaucoma and pain)


RN 61290-32-2 HCAPLUS

CN Thiourea, N-[(4-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 366786-91-6 HCAPLUS

CN Thiourea, N-[(3-chloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thiourea derivs., prepn. and use in treatment of glaucoma and pain)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:675989 HCAPLUS

DOCUMENT NUMBER: 137:216704

TITLE: 2-Hydroxyethylthioureas useful as modulators of $\alpha 2B$ adrenergic receptors

INVENTOR(S): Chow, Ken; Gil, Daniel W.; Fang, Wenkui Ken; Garst, Michael E.

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA; Allergan, Inc.

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002068384	A2	20020906	WO 2002-US5021	20020219
WO 2002068384	A3	20030306		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002161051 A1 20021031 US 2001-794874 20010227
 US 6534542 B2 20030318
 CA 2439838 AA 20020906 CA 2002-2439838 20020219
 EP 1381593 A2 20040121 EP 2002-707824 20020219
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004524312 T2 20040812 JP 2002-567898 20020219
 PRIORITY APPLN. INFO.: US 2001-794874 A 20010227
 WO 2002-US5021 W 20020219

OTHER SOURCE(S): MARPAT 137:216704
 GI



AB Thioureas I [X = (un)substituted CH₂, CH₂CH₂, CH₂CH₂CH₂; X₁ = bond, CH₂; R-R₂ = H, alkyl, alkenyl, alkynyl, OH, alkoxy, acyloxy, F, Cl, Br, I; R₃ = H, acyl] and their ring-unsatd. analogs were prepared I specifically or selectively modulate α 2B and/or α 2C **adrenergic** receptors in preference over α 2A **adrenergic** receptors and are useful for alleviating chronic pain and allodynia with no or only minimal cardiovascular and/or sedative side-effects. Thus, 3-cyclohexene-1-carboxaldehyde was reduced to the alc., which was mesylated, converted to azide, and treated with CS₂ and HOCH₂CH₂NH₂ to give 1-(1-cyclohexen-4-yl)methyl-3-(2-hydroxyethyl)thiourea (II). II had EC₅₀ 17 nM in the RSAT test.


IT 455255-92-2P 455255-94-4P 455255-95-5P
 455255-98-8P 455255-99-9P 455256-00-5P
 455256-01-6P 455256-08-3P 455256-09-4P
 455256-10-7P 455256-11-8P 455256-12-9P
 455256-13-0P 455256-14-1P 455256-15-2P
 455256-16-3P 455256-17-4P 455256-18-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 2-hydroxyethylthioureas useful as modulators of α 2B **adrenergic** receptors)

RN 455255-92-2 HCAPLUS


CN Thiourea, N-(cyclohexylmethyl)-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 455255-94-4 HCAPLUS
 CN Thiourea, N-(1-cyclohexen-1-ylmethyl)-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 455255-95-5 HCAPLUS
 CN Thiourea, N-(2-cyclohexen-1-ylmethyl)-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 455255-98-8 HCAPLUS
 CN Thiourea, N-(3-cyclohexen-1-ylmethyl)-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 455255-99-9 HCAPLUS
 CN Thiourea, N-(cyclopentylmethyl)-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 455256-00-5 HCAPLUS
CN Thiourea, N-(cycloheptylmethyl)-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 455256-01-6 HCAPLUS
CN Thiourea, N-(2-hydroxyethyl)-N'-[(6-methyl-3-cyclohexen-1-yl)methyl]- (9CI) (CA INDEX NAME)




RN 455256-08-3 HCAPLUS
CN Thiourea, N-[(2-bromo-1-cyclohexen-1-yl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 455256-09-4 HCAPLUS
CN Thiourea, N-[(3-ethyl-2-cyclohexen-1-yl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 455256-10-7 HCAPLUS
CN Thiourea, N-(2-hydroxyethyl)-N'-[(3-methyl-2-cyclohexen-1-yl)methyl]- (9CI) (CA INDEX NAME)




RN 455256-11-8 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2-methyl-2-cyclohexen-1-yl)methyl]-
(9CI) (CA INDEX NAME)




RN 455256-12-9 HCAPLUS

CN Thiourea, N-[(2-ethyl-2-cyclohexen-1-yl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 455256-13-0 HCAPLUS

CN Thiourea, N-[(2-methyl-1-cyclohexen-1-yl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 455256-14-1 HCAPLUS


CN Thiourea, N-[(2-ethyl-1-cyclohexen-1-yl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 455256-15-2 HCAPLUS
CN Thiourea, N-[(2-butyl-1-cyclopenten-1-yl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 455256-16-3 HCAPLUS
CN Thiourea, N-[(2-butyl-2-cyclopenten-1-yl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)



RN 455256-17-4 HCAPLUS
CN Thiourea, N-(2-hydroxyethyl)-N'-[(2-methyl-1-cyclopenten-1-yl)methyl]-
(9CI) (CA INDEX NAME)



RN 455256-18-5 HCAPLUS
CN Thiourea, N-(2-hydroxyethyl)-N'-[(3-methyl-1-cyclopenten-1-yl)methyl]-
(9CI) (CA INDEX NAME)



L19 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:521523 HCAPLUS
DOCUMENT NUMBER: 137:73273
TITLE: **Adrenergic** receptor ligand-neurotoxin
conjugates and methods for treating **pain**
INVENTOR(S): Gil, Daniel W.; Aoki, Kei Roger
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053177	A2	20020711	WO 2001-US48651	20011214
WO 2002053177	A3	20030918		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6787517	B1	20040907	US 2000-751053	20001229
CA 2433332	AA	20020711	CA 2001-2433332	20011214
EP 1363674	A2	20031126	EP 2001-990212	20011214
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004146532	A1	20040729	US 2004-791434	20040301
PRIORITY APPLN. INFO.:			US 2000-751053	A 20001229
			WO 2001-US48651	W 20011214


OTHER SOURCE(S): MARPAT 137:73273

AB Agents for treating **pain**, methods for producing the agents, and methods for treating **pain** by administration to a patient of a therapeutically effective amount of the agent, are disclosed. The agent may include a clostridial neurotoxin, a fragment or a derivative thereof, attached to a targeting component, wherein the targeting component is selected from a group consisting of compds. which selectively binds at the $\alpha 2b$ or $\alpha 2c$ **adrenergic** receptor subtype(s) as compared to other binding sites, e.g. the $\alpha 2a$ **adrenergic** receptor subtype.

IT **61290-32-2D**, conjugates **366786-91-6D**, conjugates
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (**adrenergic** receptor ligand-neurotoxin conjugates and methods for treating **pain**)


RN 61290-32-2 HCAPLUS

CN Thiourea, N-[(4-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 366786-91-6 HCAPLUS

CN Thiourea, N-[(3-chloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



L19 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:369027 HCAPLUS

DOCUMENT NUMBER: 136:363872

TITLE: Preparation of thiourea compounds for modulating α -adrenergic receptor activity and use in the treatment of **pain**

INVENTOR(S): Chow, Ken; Gil, Daniel W.; Fang, Wenkui; Garst, Michael E.; Wheeler, Larry A.

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 548,315, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002058839	A1	20020516	US 2001-778975	20010205
US 6545182	B2	20030408		
PRIORITY APPLN. INFO.:			US 2000-548315	B2 20000413
OTHER SOURCE(S):	MARPAT	136:363872		

GI



I

AB Methods and compns. are disclosed which use thiourea compds. I (R1, R5 = halo, alkyl, alkoxy, etc.; R2, R4 = halo, alkyl, alkoxy, etc.; R3 = F, H), and alkyl esters thereof, for the treatment of **pain**. Preparation of I [R1 = F; R2 = Cl; R3-R5 = H] which showed EC50 of 16 nM and 457 nM at α 2B and α 2C receptor in RSAT assay, was given. Particularly disclosed are compns. for the treatment of chronic **pain**, and methods for their use.

IT 61290-32-2P 61290-44-6P 61290-46-8P
 61290-47-9P 74548-54-2P 74787-66-9P
 366786-78-9P 366786-79-0P 366786-80-3P
 366786-81-4P 366786-82-5P 366786-83-6P
 366786-84-7P 366786-85-8P 366786-86-9P
 366786-87-0P 366786-89-2P 366786-90-5P


366786-91-6P 366786-92-7P 366786-93-8P
 366786-94-9P 366786-95-0P 366786-96-1P
 366786-97-2P 366786-98-3P 366786-99-4P
 366787-00-0P 366787-01-1P 366787-02-2P
 366787-03-3P 366787-04-4P 366787-05-5P
 366787-06-6P 366787-07-7P 366787-09-9P
 366787-10-2P 366787-11-3P 366787-12-4P
 366787-13-5P 366787-14-6P 366787-15-7P
 366787-16-8P 366787-17-9P 366787-18-0P
 366787-19-1P 366787-20-4P 366787-21-5P
 366787-22-6P 366787-23-7P 366787-24-8P
 366787-25-9P 366787-27-1P 366787-28-2P
 366787-29-3P 366787-30-6P 366787-31-7P
 366787-32-8P 366787-33-9P 366787-34-0P
 366787-35-1P 366787-36-2P 366787-37-3P
 366787-38-4P 366787-39-5P 366787-40-8P
 366787-41-9P 366787-42-0P 366787-43-1P
 366787-45-3P 366787-46-4P 366787-47-5P
 366787-48-6P 366787-49-7P 366787-50-0P
 366787-51-1P 366787-52-2P 366787-53-3P
 366787-54-4P 366787-55-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiourea compds. for modulating α -adrenergic receptor activity and use in treatment of pain)


RN 61290-32-2 HCAPLUS

CN Thiourea, N-[(4-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 61290-44-6 HCAPLUS

CN Thiourea, N-[(2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 61290-46-8 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 61290-47-9 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[[3-(trifluoromethyl)phenyl]methyl] - (9CI)
(CA INDEX NAME)


RN 74548-54-2 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2-methylphenyl)methyl] - (9CI) (CA INDEX NAME)




RN 74787-66-9 HCAPLUS


CN Thiourea, N-[(4-bromophenyl)methyl]-N'-(2-hydroxyethyl) - (9CI) (CA INDEX NAME)




RN 366786-78-9 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2,3,4,6-tetrafluorophenyl)methyl] - (9CI)
(CA INDEX NAME)


RN 366786-79-0 HCAPLUS

CN Thiourea, N-[(2-fluoro-6-iodophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)


RN 366786-80-3 HCAPLUS

CN Thiourea, N-[(2,6-dichlorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA
INDEX NAME)

RN 366786-81-4 HCAPLUS


CN Thiourea, N-[(2,6-difluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA
INDEX NAME)

RN 366786-82-5 HCAPLUS


CN Thiourea, N-(2-hydroxyethyl)-N'-[[3-(trifluoromethoxy)phenyl]methyl]-
(9CI) (CA INDEX NAME)

RN 366786-83-6 HCAPLUS


CN Thiourea, N-(2-hydroxyethyl)-N'-[(3-methylphenyl)methyl]- (9CI) (CA INDEX
NAME)




RN 366786-84-7 HCAPLUS
 CN Thiourea, N-(2-hydroxyethyl)-N'-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 366786-85-8 HCAPLUS
 CN Thiourea, N-(2-hydroxyethyl)-N'-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 366786-86-9 HCAPLUS
 CN Thiourea, N-[(3-chloro-4-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-87-0 HCAPLUS
 CN Thiourea, N-[(2-ethoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-89-2 HCAPLUS

CN Thiourea, N-[(2-chloro-4-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)

RN 366786-90-5 HCAPLUS


CN Thiourea, N-[(2-chloro-6-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)

RN 366786-91-6 HCAPLUS


CN Thiourea, N-[(3-chloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)

RN 366786-92-7 HCAPLUS


CN Thiourea, N-[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-93-8 HCAPLUS
CN Thiourea, N-[(2-bromophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-94-9 HCAPLUS
CN Thiourea, N-[(3-bromophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-95-0 HCAPLUS
CN Thiourea, N-[(3-chlorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 366786-96-1 HCAPLUS
CN Thiourea, N-[(2,3-dichlorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-97-2 HCAPLUS
CN Thiourea, N-[(2,3-difluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-98-3 HCAPLUS

CN Thiourea, N-[(3-bromo-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366786-99-4 HCAPLUS

CN Thiourea, N-[(3-chloro-2,6-difluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-00-0 HCAPLUS

CN Thiourea, N-[(5-chloro-2-methoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-01-1 HCAPLUS


CN Thiourea, N-[(3-fluoro-2-methoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-02-2 HCAPLUS

CN Thiourea, N-[(5-bromo-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl) - (9CI)
(CA INDEX NAME)

RN 366787-03-3 HCAPLUS


CN Thiourea, N-[(2-bromo-5-fluorophenyl)methyl]-N'-(2-hydroxyethyl) - (9CI)
(CA INDEX NAME)

RN 366787-04-4 HCAPLUS


CN Thiourea, N-[(2-fluoro-3-methoxyphenyl)methyl]-N'-(2-hydroxyethyl) - (9CI)
(CA INDEX NAME)

RN 366787-05-5 HCAPLUS


CN Thiourea, N-[(2-fluoro-5-methoxyphenyl)methyl]-N'-(2-hydroxyethyl) - (9CI)
(CA INDEX NAME)




RN 366787-06-6 HCAPLUS
 CN Thiourea, N-[(2-fluoro-5-methylphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
 (CA INDEX NAME)




RN 366787-07-7 HCAPLUS
 CN Thiourea, N-[(3-bromo-2,6-difluorophenyl)methyl]-N'-(2-hydroxyethyl)-
 (9CI) (CA INDEX NAME)




RN 366787-09-9 HCAPLUS
 CN Thiourea, N-[(5-chloro-2-fluoro-3-methylphenyl)methyl]-N'-(2-hydroxyethyl)-
 (9CI) (CA INDEX NAME)




RN 366787-10-2 HCAPLUS
 CN Thiourea, N-[(5-bromo-2-chlorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
 (CA INDEX NAME)




RN 366787-11-3 HCAPLUS
 CN Thiourea, N-[(2-bromo-5-chlorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
 (CA INDEX NAME)




RN 366787-12-4 HCAPLUS
 CN Thiourea, N-(2-hydroxyethyl)-N'-[(2,4,5-trifluorophenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 366787-13-5 HCAPLUS
 CN Thiourea, N-[(2-chloro-3-(trifluoromethyl)phenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-14-6 HCAPLUS
 CN Thiourea, N-[(3,5-dichloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-15-7 HCAPLUS
 CN Thiourea, N-(2-hydroxyethyl)-N'-[(2,3,4-trifluorophenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 366787-16-8 HCAPLUS
 CN Thiourea, N-[(3-chloro-2,4,6-trifluorophenyl)methyl]-N'-(2-hydroxyethyl)-
 (9CI) (CA INDEX NAME)



RN 366787-17-9 HCAPLUS
 CN Thiourea, N-[(6-bromo-2-fluoro-3-methylphenyl)methyl]-N'-(2-hydroxyethyl)-
 (9CI) (CA INDEX NAME)




RN 366787-18-0 HCAPLUS
 CN Thiourea, N-[(3-bromo-2-fluoro-5-methylphenyl)methyl]-N'-(2-hydroxyethyl)-
 (9CI) (CA INDEX NAME)




RN 366787-19-1 HCAPLUS

CN Thiourea, N-[(5-bromo-2-fluoro-3-methylphenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-20-4 HCAPLUS

CN Thiourea, N-[(3,5-dibromo-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-21-5 HCAPLUS

CN Thiourea, N-[(5-bromo-2,3,4-trifluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-22-6 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2,3,4-trifluoro-5-methylphenyl)methyl]-
(9CI) (CA INDEX NAME)




RN 366787-23-7 HCAPLUS

CN Thiourea, N-[(5-bromo-3-chloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-24-8 HCAPLUS

CN Thiourea, N-[(3-bromo-2-fluoro-6-methylphenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-25-9 HCAPLUS

CN Thiourea, N-[(5-chloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-27-1 HCAPLUS

CN Thiourea, N-[(2-chloro-3,6-difluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-28-2 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2-iodophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 366787-29-3 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(3-iodophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 366787-30-6 HCAPLUS

CN Thiourea, N-[(2,5-difluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-31-7 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(pentafluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 366787-32-8 HCAPLUS

CN Thiourea, N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-33-9 HCAPLUS

CN Thiourea, N-[(2-fluoro-6-methoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-34-0 HCAPLUS

CN Thiourea, N-[[5-fluoro-2-methoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-35-1 HCAPLUS

CN Thiourea, N-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-36-2 HCAPLUS

CN Thiourea, N-[(2,3-dichloro-6-fluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-37-3 HCAPLUS

CN Thiourea, N-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-38-4 HCAPLUS

CN Thiourea, N-[(3-chloro-2-fluoro-5-methylphenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-39-5 HCAPLUS

CN Thiourea, N-[(3,6-dichloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-40-8 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2,3,5,6-tetrafluorophenyl)methyl]- (9CI)
(CA INDEX NAME)




RN 366787-41-9 HCAPLUS

CN Thiourea, N-[(5-fluoro-2-hydroxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME),




RN 366787-42-0 HCAPLUS

CN Thiourea, N-[(2-fluoro-3-iodophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-43-1 HCAPLUS

CN Thiourea, N-[(2-fluoro-5-iodophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-45-3 HCAPLUS

CN Thiourea, N-[(6-bromo-2-fluoro-3-iodophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-46-4 HCAPLUS

CN Thiourea, N-[(3-bromo-2,4-difluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-47-5 HCAPLUS

CN Thiourea, N-[(6-bromo-2,3-difluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-48-6 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2,3,4,5-tetrafluorophenyl)methyl]- (9CI)
(CA INDEX NAME)




RN 366787-49-7 HCAPLUS

CN Thiourea, N-[(3,6-dibromo-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-50-0 HCAPLUS

CN Thiourea, N-[(2,3-dibromo-5,6-difluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-51-1 HCAPLUS

CN Thiourea, N-[(2-bromo-6-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-52-2 HCAPLUS

CN Thiourea, N-[[2,5-bis(trifluoromethyl)phenyl]methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-53-3 HCAPLUS

CN Thiourea, N-[(2,5-dimethoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-54-4 HCAPLUS

CN Thiourea, N-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 366787-55-5 HCAPLUS

CN Thiourea, N-[(2,3-dimethoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



L19 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 2001:780662 HCAPLUS

DOCUMENT NUMBER: 135:327361


TITLE: Methods and compositions using benzylthiourea derivatives for modulating alpha **adrenergic**

receptor activity
 INVENTOR(S): Chow, Ken; Gil, Daniel W.; Fang, Wenkui Ken; Garst, Michael E.; Wheeler, Larry A.
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
 SOURCE: PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001078703	A2	20011025	WO 2001-US11843	20010411
WO 2001078703	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6313172	B1	20011106	US 2000-548410	20000413
CA 2406057	AA	20011025	CA 2001-2406057	20010411
EP 1280525	A2	20030205	EP 2001-926876	20010411
EP 1280525	B1	20050209		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003530430	T2	20031014	JP 2001-576004	20010411
NZ 522027	A	20041126	NZ 2001-522027	20010411
PRIORITY APPLN. INFO.:			US 2000-548410	A 20000413
			WO 2001-US11843	W 20010411
OTHER SOURCE(S):			MARPAT 135:327361	
GI				




I




II


- AB The invention discloses benzylthiourea derivs. I (R1, R3 = F, H; R2 = Cl, H; with provisos, and alkyl esters thereof) as α 2- **adrenergic** receptor modulators. The invention also describes the synthesis of a compound II (wherein R1= H, R2= Cl and R3 = F). The effects of these disclosed compds. on acute and chronic **pain**, their sedative action and their cardiovascular effects are described.
- IT **61290-32-2P 61290-44-6P 366786-91-6P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (benzylthiourea derivs. for modulating alpha **adrenoceptor** activity and their application in **pain** therapy)
- RN 61290-32-2 HCAPLUS
- CN Thiourea, N-[(4-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




- RN 61290-44-6 HCAPLUS
- CN Thiourea, N-[(2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




- RN 366786-91-6 HCAPLUS
- CN Thiourea, N-[(3-chloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



- IT **61290-32-2D, alkyl esters 366786-91-6D, alkyl esters**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (benzylthiourea derivs. for modulating alpha **adrenoceptor** activity and their application in **pain** therapy)
- RN 61290-32-2 HCAPLUS
- CN Thiourea, N-[(4-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 366786-91-6 HCAPLUS
 CN Thiourea, N-[(3-chloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
 (CA INDEX NAME)



L19 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:780661 HCAPLUS

DOCUMENT NUMBER: 135:298811

TITLE: Thiourea compounds for modulating α -
adrenergic receptor activity, preparation,
 compositions, and use in the treatment of **pain**
 INVENTOR(S): Chow, Ken; Gil, Daniel W.; Fang, Wenkui Ken; Garst,
 Michael E.; Wheeler, Larry A.

PATENT ASSIGNEE(S): Allergan Sales, Inc., USA

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001078702	A2	20011025	WO 2001-US11842	20010411
WO 2001078702	A3	20020321		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2405796	AA	20011025	CA 2001-2405796	20010411
EP 1280524	A2	20030205	EP 2001-926875	20010411
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003530429	T2	20031014	JP 2001-576003	20010411
PRIORITY APPLN. INFO.:			US 2000-548315	A 20000413
			WO 2001-US11842	W 20010411

OTHER SOURCE(S): MARPAT 135:298811
GI




AB Methods and compns. are disclosed which use thiourea compds. I (R1, R2, R4, R5 = H, OH, C1-3 alkyl, etc.; R3 = H, F), and alkyl esters thereof, for the treatment of **pain**. Particularly disclosed are compns. for the treatment of chronic **pain**, and methods for their use.

IT **61290-44-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(thiourea compds. for modulating α - **adrenergic** receptor activity, preparation, compns., and use in treatment of **pain**)

RN 61290-44-6 HCAPLUS

CN Thiourea, N-[(2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



IT 61290-32-2 61290-46-8 61290-47-9
74548-54-2 74787-66-9 366786-78-9
366786-79-0 366786-80-3 366786-81-4
366786-82-5 366786-83-6 366786-84-7
366786-85-8 366786-86-9 366786-87-0
366786-89-2 366786-90-5 366786-91-6
366786-92-7 366786-93-8 366786-94-9
366786-95-0 366786-96-1 366786-97-2
366786-98-3 366786-99-4 366787-00-0
366787-01-1 366787-02-2 366787-03-3
366787-04-4 366787-05-5 366787-06-6
366787-07-7 366787-09-9 366787-10-2
366787-11-3 366787-12-4 366787-13-5
366787-14-6 366787-15-7 366787-16-8
366787-17-9 366787-18-0 366787-19-1
366787-20-4 366787-21-5 366787-22-6
366787-23-7 366787-24-8 366787-25-9
366787-27-1 366787-28-2 366787-29-3
366787-30-6 366787-31-7 366787-32-8
366787-33-9 366787-34-0 366787-35-1
366787-36-2 366787-37-3 366787-38-4
366787-39-5 366787-40-8 366787-41-9
366787-42-0 366787-43-1 366787-45-3


366787-46-4 366787-47-5 366787-48-6
 366787-49-7 366787-50-0 366787-51-1
 366787-52-2 366787-53-3 366787-54-4
 366787-55-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(thiourea compds. for modulating α -adrenergic receptor activity, preparation, compns., and use in treatment of pain)


RN 61290-32-2 HCAPLUS

CN Thiourea, N-[(4-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 61290-46-8 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 61290-47-9 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 74548-54-2 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 74787-66-9 HCAPLUS

CN Thiourea, N-[(4-bromophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-78-9 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2,3,4,6-tetrafluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 366786-79-0 HCAPLUS

CN Thiourea, N-[(2-fluoro-6-iodophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-80-3 HCAPLUS

CN Thiourea, N-[(2,6-dichlorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-81-4 HCAPLUS

CN Thiourea, N-[(2,6-difluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-82-5 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[[3-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 366786-83-6 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(3-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 366786-84-7 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 366786-85-8 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 366786-86-9 HCAPLUS

CN Thiourea, N-[(3-chloro-4-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366786-87-0 HCAPLUS

CN Thiourea, N-[(2-ethoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-89-2 HCAPLUS

CN Thiourea, N-[(2-chloro-4-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366786-90-5 HCAPLUS

CN Thiourea, N-[(2-chloro-6-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366786-91-6 HCAPLUS

CN Thiourea, N-[(3-chloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366786-92-7 HCAPLUS

CN Thiourea, N-[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-93-8 HCAPLUS

CN Thiourea, N-[(2-bromophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-94-9 HCAPLUS

CN Thiourea, N-[(3-bromophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-95-0 HCAPLUS

CN Thiourea, N-[(3-chlorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-96-1 HCAPLUS

CN Thiourea, N-[(2,3-dichlorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-97-2 HCAPLUS

CN Thiourea, N-[(2,3-difluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-98-3 HCAPLUS


CN Thiourea, N-[(3-bromo-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366786-99-4 HCAPLUS
CN Thiourea, N-[(3-chloro-2,6-difluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-00-0 HCAPLUS
CN Thiourea, N-[(5-chloro-2-methoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-01-1 HCAPLUS
CN Thiourea, N-[(3-fluoro-2-methoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-02-2 HCAPLUS
CN Thiourea, N-[(5-bromo-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-03-3 HCAPLUS
CN Thiourea, N-[(2-bromo-5-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-04-4 HCAPLUS
 CN Thiourea, N-[(2-fluoro-3-methoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
 (CA INDEX NAME)




RN 366787-05-5 HCAPLUS
 CN Thiourea, N-[(2-fluoro-5-methoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
 (CA INDEX NAME)



RN 366787-06-6 HCAPLUS
 CN Thiourea, N-[(2-fluoro-5-methylphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
 (CA INDEX NAME)




RN 366787-07-7 HCAPLUS
 CN Thiourea, N-[(3-bromo-2,6-difluorophenyl)methyl]-N'-(2-hydroxyethyl)-
 (9CI) (CA INDEX NAME)




RN 366787-09-9 HCAPLUS

CN Thiourea, N-[(5-chloro-2-fluoro-3-methylphenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-10-2 HCAPLUS

CN Thiourea, N-[(5-bromo-2-chlorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-11-3 HCAPLUS

CN Thiourea, N-[(2-bromo-5-chlorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-12-4 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2,4,5-trifluorophenyl)methyl]- (9CI)
(CA INDEX NAME)




RN 366787-13-5 HCAPLUS

CN Thiourea, N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-14-6 HCAPLUS

CN Thiourea, N-[(3,5-dichloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-15-7 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2,3,4-trifluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 366787-16-8 HCAPLUS

CN Thiourea, N-[(3-chloro-2,4,6-trifluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-17-9 HCAPLUS

CN Thiourea, N-[(6-bromo-2-fluoro-3-methylphenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-18-0 HCAPLUS

CN Thiourea, N-[(3-bromo-2-fluoro-5-methylphenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-19-1 HCAPLUS

CN Thiourea, N-[(5-bromo-2-fluoro-3-methylphenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-20-4 HCAPLUS

CN Thiourea, N-[(3,5-dibromo-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-21-5 HCAPLUS

CN Thiourea, N-[(5-bromo-2,3,4-trifluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-22-6 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2,3,4-trifluoro-5-methylphenyl)methyl]-
(9CI) (CA INDEX NAME)




RN 366787-23-7 HCAPLUS

CN Thiourea, N-[(5-bromo-3-chloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-24-8 HCAPLUS

CN Thiourea, N-[(3-bromo-2-fluoro-6-methylphenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-25-9 HCAPLUS

CN Thiourea, N-[(5-chloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-27-1 HCAPLUS

CN Thiourea, N-[(2-chloro-3,6-difluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-28-2 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2-iodophenyl)methyl]- (9CI) (CA INDEX
NAME)




RN 366787-29-3 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(3-iodophenyl)methyl]- (9CI) (CA INDEX
NAME)




RN 366787-30-6 HCAPLUS

CN Thiourea, N-[(2,5-difluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-31-7 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(pentafluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 366787-32-8 HCAPLUS

CN Thiourea, N-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-33-9 HCAPLUS

CN Thiourea, N-[(2-fluoro-6-methoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-34-0 HCAPLUS

CN Thiourea, N-[(5-fluoro-2-methoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-35-1 HCAPLUS

CN Thiourea, N-[[2-fluoro-6-(trifluoromethyl)phenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-36-2 HCAPLUS

CN Thiourea, N-[(2,3-dichloro-6-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-37-3 HCAPLUS

CN Thiourea, N-[[2-fluoro-5-(trifluoromethyl)phenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)




RN 366787-38-4 HCAPLUS

CN Thiourea, N-[(3-chloro-2-fluoro-5-methylphenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-39-5 HCAPLUS

CN Thiourea, N-[(3,6-dichloro-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-40-8 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2,3,5,6-tetrafluorophenyl)methyl]- (9CI)
(CA INDEX NAME)




RN 366787-41-9 HCAPLUS

CN Thiourea, N-[(5-fluoro-2-hydroxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-42-0 HCAPLUS

CN Thiourea, N-[(2-fluoro-3-iodophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-43-1 HCAPLUS

CN Thiourea, N-[(2-fluoro-5-iodophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)




RN 366787-45-3 HCAPLUS

CN Thiourea, N-[(6-bromo-2-fluoro-3-iodophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-46-4 HCAPLUS

CN Thiourea, N-[(3-bromo-2,4-difluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-47-5 HCAPLUS

CN Thiourea, N-[(6-bromo-2,3-difluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-48-6 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-[(2,3,4,5-tetrafluorophenyl)methyl]- (9CI)
(CA INDEX NAME)




RN 366787-49-7 HCAPLUS

CN Thiourea, N-[(3,6-dibromo-2-fluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-50-0 HCAPLUS


CN Thiourea, N-[(2,3-dibromo-5,6-difluorophenyl)methyl]-N'-(2-hydroxyethyl)-
(9CI) (CA INDEX NAME)




RN 366787-51-1 HCAPLUS
 CN Thiourea, N-[(2-bromo-6-fluorophenyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
 (CA INDEX NAME)




RN 366787-52-2 HCAPLUS
 CN Thiourea, N-[[2,5-bis(trifluoromethyl)phenyl]methyl]-N'-(2-hydroxyethyl)-
 (9CI) (CA INDEX NAME)




RN 366787-53-3 HCAPLUS
 CN Thiourea, N-[(2,5-dimethoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA
 INDEX NAME)




RN 366787-54-4 HCAPLUS
 CN Thiourea, N-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-N'-(2-
 hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 366787-55-5 HCAPLUS
 CN Thiourea, N-[(2,3-dimethoxyphenyl)methyl]-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



L19 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1992:6459 HCAPLUS
 DOCUMENT NUMBER: 116:6459
 TITLE: Synthesis and biological activity of
 2-aminothiazolines and 2-mercaptothiazolines as
 octopaminergic agonists
 AUTHOR(S): Hirashima, Akinori; Yoshii, Yutaka; Eto, Morifusa
 CORPORATE SOURCE: Dep. Agric. Chem., Kyushu Univ., Fukuoka, 812, Japan
 SOURCE: Agricultural and Biological Chemistry (1991), 55(10),
 2537-45
 CODEN: ABCHA6; ISSN: 0002-1369
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The title compds., e.g., I (R = H, Me, Ph, Et, CH₂CH₂SMe; R₁ = alkyl- or arylamino, SH, EtO₂CCH₂S) were prepared by the cyclocondensation of the corresponding isothiocyanates or CS₂ with ethanolamines or their sulfates. I [R = H, R₁ = 2-Me-4-ClC₆H₃NH (II)] was 33% as effective as octopamine at 100 μM in stimulating adenylate cyclase of *Periplaneta americana* ventral-nerve-cord homogenates. Its activity was nonadditive to the activity of octopamine. Stimulation of nerve-cord adenylate-cyclase activity by II was inhibited by several antagonists, including mianserin, cyproheptadine, chlorpromazine and gramine. The rank-order ability of these antagonists to block the activation by II was identical to the


rank-order ability of the same antagonists to block enzyme activation by octopamine. The β -adrenergic antagonist propranolol was less potent. These data suggest that II is a potent and selective agonist of octopamine-activated adenylate cyclase. Aminothiazolines, which activated adenylate cyclase by 10-87% relative to octopamine also had acaricidal activity at 300 ppm, indicating a correlation between the in vitro octopaminergic-agonist activity and in vivo acaricidal activity of aminothiazolines.

IT 6098-41-5 27803-70-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(cyclocondensation of, with isothiocyanates)


RN 6098-41-5 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 27803-70-9 HCAPLUS

CN Thiourea, N-butyl-N'-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



L19 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1987:458972 HCAPLUS

DOCUMENT NUMBER: 107:58972

TITLE: Investigations on the reaction course of diethyl 2-chloro-6-methylpyridine-3,5-dicarboxylate with N-amino- and N-hydroxyalkyl derivatives of thiourea

AUTHOR(S): Sladowska, H.; Bartoszko-Malik, A.; Zawisza, T.

CORPORATE SOURCE: Dep. Chem. Drugs, Sch. Med., Wroclaw, Pol.

SOURCE: Farmaco, Edizione Scientifica (1986), 41(11), 899-912



CODEN: FRPSAX; ISSN: 0430-0920

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 107:58972

GI



AB Pyridopyrimidines I (R1 = Me, Ph) and pyridothiazines II (R2 = H, Me) were prepared, and they exhibited **analgesic** activity. The title

dinicotinate ester was heated with MeNHCSNHCH₂CH₂N+HET₂ Cl⁻ in EtOH to give I (R₁ = Me).


IT 105-81-7 3120-26-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(cyclocondensation reaction of, with chloronicotinic acid derivative)


RN 105-81-7 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-2-propenyl- (9CI) (CA INDEX NAME)



RN 3120-26-1 HCAPLUS

CN Thiourea, N-(2-hydroxyethyl)-N'-methyl- (9CI) (CA INDEX NAME)



L19 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1972:564591 HCAPLUS

DOCUMENT NUMBER: 77:164591

TITLE: Benzofurans. Benzofurarylmethylimidazolines

AUTHOR(S): Areschka, A.; Prost, M.; Mahaux, J. M.; Van Cromphaut, V.; Verbruggen, F.; Binon, F.; Charlier, R.; Delaunois, G.; Colot, M.; et al.

CORPORATE SOURCE: Cent. Rech. S. A.-Labaz N. V., Brussels, Belg.

SOURCE: Chimica Therapeutica (1972), 7(4), 337-44

CODEN: CHTPBA; ISSN: 0009-4374

DOCUMENT TYPE: Journal

LANGUAGE: French

GI For diagram(s), see printed CA Issue.


AB Benzofuranimid-azolines including I (R = Me, Et, Ph, CHMe₂, Bu), 2-(4-benzo-furyloxymethyl)imidazoline (II), 2-(7-benzofuryloxymethyl)-imidazoline (III), 2-(2-ethyl-3-benzofurylmethylamino)imidazo-line (IV), 2-[2-(7-benzofuryloxy)ethylamino]imidazoline (V), and 2-(5-benzofurylmethylamino)imidazoline (VI) were prepared, e.g. by formylating the benzofuran, forming the chloroalkyl and then the cyanoalkyl derivative and then the imidoic ester, which was cyclized with H₂NCH₂CH₂NH₂. I had hypertensive activity in the dog at concns. 0.1-0.2 times that of adranaline. II and III were antihypertensive in rats at 25 mg/kg. IV-VI had antiinflamma-tory activity similar to that of aspirin, but no **analgesic** activity.

IT 37813-05-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 37813-05-1 HCAPLUS

CN Thiourea, N-[(2-ethyl-3-benzofuranyl)methyl]-N'-(2-hydroxyethyl)- (9CI)
(CA INDEX NAME)



? b biosci, 431, 55, 165

Set	Items	Description
S1	228763	ALPHA2 OR (ALPHA())2
S2	551911	ADRENERGIC
S3	4273782	CONJUGAT? OR FUSION OR TARGET? OR COUPLE?
S4	1156789	PAIN
S5	158	S1 AND S2 AND S3 AND S4
S6	97	RD (unique items)
S7	40	S6 AND PY<2001

? t s7/full/25

S1	56213	PRAZOSIN
S2	2280184	COUPLE? OR CONJUGATE? OR FUSION
S3	1206888	PAIN OR NOCICEPT?
S4	1480	S1 AND S2
S5	16	S4 AND S3
S6	13	RD (unique items)
S7	128951	NALTREXONE OR NALOXONE
S8	315208	(ALPHA AND (ADRENERGIC)) OR ADRENOCEPT? OR ADRENORECEPT?
S9	292865	8 (3N) (B OR C)
S10	8241	S8 (3N) (B OR C)
S11	140	S10 AND S7
S12	29	S11 AND S3
S13	15	RD (unique items)
S14	2458	S7 AND S2
S15	434	S14 AND S3
S16	1855	S7 (S) S2
S17	271	S16 (S) S3
S18	78	RD (unique items)
S19	53	S18 AND PY<2001
S20	221	IMILOXAN
S21	622	ARC239 OR (ARC())239
S22	56509	S20 OR S21 OR S1
S23	3929025	CONJUGAT? OR FUSION OR LINK? OR FUSE?
S24	905	S22 (S) S23
S25	10	S3 AND S24
S26	6	RD (unique items)
S27	1902	S10 (5N) (AGONIST? OR ANTAGONIST?)
S28	66	S23 AND S27
S29	1	S28 AND S3